{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-005091","form_type":"8-K","ticker":"ALEC","cik":"0001653087","company_name":"Alector, Inc.","filed_at":"2023-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.019977+00:00","generated_at":"2026-06-18T22:16:59.963380+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Alector reports Q4 2022 net loss of $52.4M; cash runway through 2025","bullets":["Net loss Q4 2022: $52.4M ($0.63/share) vs $55.6M ($0.68) in Q4 2021; full-year net loss $133.3M ($1.62) vs $36.3M ($0.45).","Cash, cash equivalents, investments $712.9M as of Dec 31, 2022; management expects runway through 2025.","2023 guidance: collaboration revenue $15-25M, R&D expenses $225-245M, G&A expenses $60-70M.","INVOKE-2 Phase 2 enrollment completion expected Q3 2023, data by Q4 2024; $17.8M milestone from AbbVie triggered.","INFRONT-3 pivotal trial for latozinemab: regulatory engagement mid-2023, data readout early 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-005091","json":"https://secwatch.observer/filing/0000950170-23-005091.json","markdown":"https://secwatch.observer/filing/0000950170-23-005091.md","text":"https://secwatch.observer/filing/0000950170-23-005091.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1653087/000095017023005091/0000950170-23-005091-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1653087/000095017023005091/alec-20230228.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T22:16:59.963380+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3f57e4103bde5a1cf6791a609fab779a207df3a0","claim":"Alector, Inc. reported financial results for the quarter ended December 31, 2022.","evidence_excerpt":"On February 28, 2023, Alector, Inc. (the “Company”) announced its financial results for the quarter ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1653087/000095017023005091/0000950170-23-005091-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}